Unknown

Dataset Information

0

Precision glycocalyx editing as a strategy for cancer immunotherapy.


ABSTRACT: Cell surface sialosides constitute a central axis of immune modulation that is exploited by tumors to evade both innate and adaptive immune destruction. Therapeutic strategies that target tumor-associated sialosides may therefore potentiate antitumor immunity. Here, we report the development of antibody-sialidase conjugates that enhance tumor cell susceptibility to antibody-dependent cell-mediated cytotoxicity (ADCC) by selective desialylation of the tumor cell glycocalyx. We chemically fused a recombinant sialidase to the human epidermal growth factor receptor 2 (HER2)-specific antibody trastuzumab through a C-terminal aldehyde tag. The antibody-sialidase conjugate desialylated tumor cells in a HER2-dependent manner, reduced binding by natural killer (NK) cell inhibitory sialic acid-binding Ig-like lectin (Siglec) receptors, and enhanced binding to the NK-activating receptor natural killer group 2D (NKG2D). Sialidase conjugation to trastuzumab enhanced ADCC against tumor cells expressing moderate levels of HER2, suggesting a therapeutic strategy for cancer patients with lower HER2 levels or inherent trastuzumab resistance. Precision glycocalyx editing with antibody-enzyme conjugates is therefore a promising avenue for cancer immune therapy.

SUBMITTER: Xiao H 

PROVIDER: S-EPMC5027407 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Precision glycocalyx editing as a strategy for cancer immunotherapy.

Xiao Han H   Woods Elliot C EC   Vukojicic Petar P   Bertozzi Carolyn R CR  

Proceedings of the National Academy of Sciences of the United States of America 20160822 37


Cell surface sialosides constitute a central axis of immune modulation that is exploited by tumors to evade both innate and adaptive immune destruction. Therapeutic strategies that target tumor-associated sialosides may therefore potentiate antitumor immunity. Here, we report the development of antibody-sialidase conjugates that enhance tumor cell susceptibility to antibody-dependent cell-mediated cytotoxicity (ADCC) by selective desialylation of the tumor cell glycocalyx. We chemically fused a  ...[more]

Similar Datasets

| S-EPMC7312441 | biostudies-literature
2024-07-21 | GSE244808 | GEO
| S-EPMC7470800 | biostudies-literature
| S-EPMC6133985 | biostudies-literature
| S-EPMC7409312 | biostudies-literature
| S-EPMC5455211 | biostudies-literature
| S-EPMC8507967 | biostudies-literature
| S-EPMC8752797 | biostudies-literature
| S-EPMC5709224 | biostudies-literature
| S-EPMC11295146 | biostudies-literature